232 related articles for article (PubMed ID: 26507655)
1. Mapping the Binding Site of the Inhibitor Tariquidar That Stabilizes the First Transmembrane Domain of P-glycoprotein.
Loo TW; Clarke DM
J Biol Chem; 2015 Dec; 290(49):29389-401. PubMed ID: 26507655
[TBL] [Abstract][Full Text] [Related]
2. Cysteines introduced into extracellular loops 1 and 4 of human P-glycoprotein that are close only in the open conformation spontaneously form a disulfide bond that inhibits drug efflux and ATPase activity.
Loo TW; Clarke DM
J Biol Chem; 2014 Sep; 289(36):24749-58. PubMed ID: 25053414
[TBL] [Abstract][Full Text] [Related]
3. Tariquidar inhibits P-glycoprotein drug efflux but activates ATPase activity by blocking transition to an open conformation.
Loo TW; Clarke DM
Biochem Pharmacol; 2014 Dec; 92(4):558-66. PubMed ID: 25456855
[TBL] [Abstract][Full Text] [Related]
4. Thiol-reactive drug substrates of human P-glycoprotein label the same sites to activate ATPase activity in membranes or dodecyl maltoside detergent micelles.
Loo TW; Clarke DM
Biochem Biophys Res Commun; 2017 Jul; 488(4):573-577. PubMed ID: 28533092
[TBL] [Abstract][Full Text] [Related]
5. Drug-protein hydrogen bonds govern the inhibition of the ATP hydrolysis of the multidrug transporter P-glycoprotein.
Chufan EE; Kapoor K; Ambudkar SV
Biochem Pharmacol; 2016 Feb; 101():40-53. PubMed ID: 26686578
[TBL] [Abstract][Full Text] [Related]
6. Suppressor mutations in the transmembrane segments of P-glycoprotein promote maturation of processing mutants and disrupt a subset of drug-binding sites.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2007 Nov; 282(44):32043-52. PubMed ID: 17848563
[TBL] [Abstract][Full Text] [Related]
7. The Transmission Interfaces Contribute Asymmetrically to the Assembly and Activity of Human P-glycoprotein.
Loo TW; Clarke DM
J Biol Chem; 2015 Jul; 290(27):16954-63. PubMed ID: 25987565
[TBL] [Abstract][Full Text] [Related]
8. Processing mutations disrupt interactions between the nucleotide binding and transmembrane domains of P-glycoprotein and the cystic fibrosis transmembrane conductance regulator (CFTR).
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2008 Oct; 283(42):28190-7. PubMed ID: 18708637
[TBL] [Abstract][Full Text] [Related]
9. Identification of residues in the drug translocation pathway of the human multidrug resistance P-glycoprotein by arginine mutagenesis.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2009 Sep; 284(36):24074-87. PubMed ID: 19581304
[TBL] [Abstract][Full Text] [Related]
10. Locking intracellular helices 2 and 3 together inactivates human P-glycoprotein.
Loo TW; Clarke DM
J Biol Chem; 2014 Jan; 289(1):229-36. PubMed ID: 24275649
[TBL] [Abstract][Full Text] [Related]
11. Processing mutations located throughout the human multidrug resistance P-glycoprotein disrupt interactions between the nucleotide binding domains.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2004 Sep; 279(37):38395-401. PubMed ID: 15247215
[TBL] [Abstract][Full Text] [Related]
12. Insertion of an arginine residue into the transmembrane segments corrects protein misfolding.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2006 Oct; 281(40):29436-40. PubMed ID: 16926162
[TBL] [Abstract][Full Text] [Related]
13. Arginines in the first transmembrane segment promote maturation of a P-glycoprotein processing mutant by hydrogen bond interactions with tyrosines in transmembrane segment 11.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2008 Sep; 283(36):24860-70. PubMed ID: 18596043
[TBL] [Abstract][Full Text] [Related]
14. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2003 Apr; 278(16):13603-6. PubMed ID: 12609990
[TBL] [Abstract][Full Text] [Related]
15. The ATPase activity of the P-glycoprotein drug pump is highly activated when the N-terminal and central regions of the nucleotide-binding domains are linked closely together.
Loo TW; Bartlett MC; Detty MR; Clarke DM
J Biol Chem; 2012 Aug; 287(32):26806-16. PubMed ID: 22700974
[TBL] [Abstract][Full Text] [Related]
16. Human P-glycoprotein contains a greasy ball-and-socket joint at the second transmission interface.
Loo TW; Bartlett MC; Clarke DM
J Biol Chem; 2013 Jul; 288(28):20326-33. PubMed ID: 23733192
[TBL] [Abstract][Full Text] [Related]
17. Effects of a detergent micelle environment on P-glycoprotein (ABCB1)-ligand interactions.
Shukla S; Abel B; Chufan EE; Ambudkar SV
J Biol Chem; 2017 Apr; 292(17):7066-7076. PubMed ID: 28283574
[TBL] [Abstract][Full Text] [Related]
18. Nucleotide binding, ATP hydrolysis, and mutation of the catalytic carboxylates of human P-glycoprotein cause distinct conformational changes in the transmembrane segments.
Loo TW; Bartlett MC; Clarke DM
Biochemistry; 2007 Aug; 46(32):9328-36. PubMed ID: 17636884
[TBL] [Abstract][Full Text] [Related]
19. ATP-dependent thermostabilization of human P-glycoprotein (ABCB1) is blocked by modulators.
Lusvarghi S; Ambudkar SV
Biochem J; 2019 Dec; 476(24):3737-3750. PubMed ID: 31774117
[TBL] [Abstract][Full Text] [Related]
20. Attachment of a 'molecular spring' restores drug-stimulated ATPase activity to P-glycoprotein lacking both Q loop glutamines.
Loo TW; Clarke DM
Biochem Biophys Res Commun; 2017 Jan; 483(1):366-370. PubMed ID: 28025146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
